SVB Leerink Downgrades Recursion Pharmaceuticals (RXRX) to Market Perform

March 4, 2022 6:13 AM EST Send to a Friend
SVB Leerink analyst Mani Foroohar downgraded Recursion Pharmaceuticals (NASDAQ: RXRX) from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login